GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (NAS:SVRA) » Definitions » Net Current Asset Value

Savara (Savara) Net Current Asset Value : $0.93 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Savara Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Savara's net current asset value per share for the quarter that ended in Dec. 2023 was $0.93.

The historical rank and industry rank for Savara's Net Current Asset Value or its related term are showing as below:

SVRA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.06   Med: 2.55   Max: 7.85
Current: 5.06

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Savara was 7.85. The lowest was 1.06. And the median was 2.55.

SVRA's Price-to-Net-Current-Asset-Value is ranked worse than
58.29% of 1031 companies
in the Biotechnology industry
Industry Median: 4.08 vs SVRA: 5.06

Savara Net Current Asset Value Historical Data

The historical data trend for Savara's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Net Current Asset Value Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.76 0.96 1.17 0.85 0.93

Savara Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.76 0.66 0.99 0.93

Competitive Comparison of Savara's Net Current Asset Value

For the Biotechnology subindustry, Savara's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savara's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Savara's Price-to-Net-Current-Asset-Value falls into.



Savara Net Current Asset Value Calculation

Savara's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(165.947-37.192-0-0)/138.144
=0.93

Savara's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(165.947-37.192-0-0)/138.144
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Savara  (NAS:SVRA) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Savara Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Savara's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Savara (Savara) Business Description

Traded in Other Exchanges
Address
6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Executives
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
David L Lowrance officer: Chief Financial Officer 422 WILLIAM WALLACE DRIVE, FRANKLIN TN 37064
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Growth Equity Opportunities 17, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Raymond Dennis Pratt officer: Chief Medical Officer 208 E CHASE ST, BALTIMORE MD 21202
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121

Savara (Savara) Headlines

From GuruFocus

Savara Announces New Employment Inducement Grant

By Business Wire Business Wire 03-31-2023

Savara to Participate in Three Upcoming Investor Conferences

By Business Wire Business Wire 11-09-2022

Savara Announces Resignation of Chief Medical Officer

By Business Wire Business Wire 08-26-2022

Savara Announces New Leadership Appointments

By Business Wire Business Wire 02-14-2023

Savara Announces New Employment Inducement Grant

By Business Wire 08-04-2023

Savara Announces New Employment Inducement Grant

By Business Wire 10-06-2023